Core Viewpoint - A class action securities lawsuit has been filed against Kyverna Therapeutics, Inc. due to alleged securities fraud related to its February 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who purchased Kyverna common stock based on the company's offering documents from its IPO [2]. - The complaint alleges that the defendants made false statements and concealed critical information regarding the IPO strategy, terms, and disclosures in the offering documents [3]. - It is claimed that the underwriter defendants should have been aware of Kyverna's undisclosed issues and the misleading nature of the offering documents due to ongoing communications with the company's management [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Kyverna Therapeutics, Inc. during the relevant period have until February 7, 2025, to request appointment as lead plaintiff [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [4]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

Core Viewpoint - A class action lawsuit has been filed against Kyverna Therapeutics, Inc. and its executives for alleged violations of federal securities laws related to its IPO on February 8, 2024, due to misleading statements and undisclosed negative information about clinical trials [1][6]. Group 1: Lawsuit Details - The lawsuit represents all individuals and entities that purchased Kyverna common stock during its IPO, which offered 14.5 million shares at $22.00 per share, raising approximately $296 million in net proceeds [5]. - Investors have until February 7, 2025, to seek appointment as lead plaintiff in the class action lawsuit [2]. Group 2: Allegations Against Kyverna - The lawsuit alleges that the IPO registration statement contained false and misleading statements, including failure to disclose negative information about a clinical trial that adversely affected Kyverna's main product [6]. - It is claimed that the company's risk disclosures were inadequate, failing to address the potential negative impacts on future results and share price due to undisclosed adverse information [6]. Group 3: Impact of Disclosure - The truth about the negative clinical trial data emerged on June 14, 2024, leading to a significant decline in Kyverna's stock price, which fell over 82% to as low as $3.92 per share by the time the lawsuit was filed [7].

NEW YORK, Dec. 12, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to the Company's initial public offering conducted on February 8, 2024 (the "IPO"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 7, 2025.So what: If you purchased Kyverna com ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Kyverna To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 investing Kyverna common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 8, 2024 (the "IPO" or "Offering") and would like to discuss your legal rights, call Faru ...

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Kyverna securities pursuant and/or traceable to the Company's offering documents issued in connection wi ...

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna” or “the Company”) (NASDAQ: KYTX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kyv ...

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) common stock pursuant and/or traceable to Kyverna’s registration statement issued in connection with Kyverna’s initial public offering (“IPO”) held on February 8, 2024, have until February 7, 2025 to seek appointment as lead plaintiff of the Kyverna class action lawsuit. Captioned Rondini v. Kyverna Therapeutics, Inc., No. 24-cv-08869 (N.D. Cal.), ...

LOS ANGELES, Dec. 11, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ: KYTX) for violations of the federal securities laws.Investors who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |-------------------------------------------------------------------------------------|---------------------------------| | | | | For the transition period from ____________ ...

Exhibit 99.1 Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance Broad KYSA Clinical Development Program: Presented Clinical Data Highlighting Potential for KYV-101 in SPS, MG and MS at ECTRIMS and Plan to Share Updated Clinical Data in LN at Company Symposium at ACR Convergence 2024 Strong Financial Posit ...